



# Lyka Labs Limited



## MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,  
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry @ lykalabs.com

### STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2012

| Particulars  | 3 Months             | 3 Months              | Corresponding  | Year To Date  | Year To Date  | (Rs.in Lacs)  |
|--|----------------------|-----------------------|--|---|---|---|
|  | Ended<br>31-Dec-2012 | Ended<br>30-Sept-2012 | 3 Months<br>Ended in the<br>previous year<br>31-Dec-2011 | Figures For<br>Current period<br>ended<br>31-Dec-2012<br>(9 months) | Figures For the<br>period ended<br>31-Dec-2011<br>(15 months) | Previous<br>Accounting<br>year ended 31-<br>March-2012<br>(18 months) |
|  | (Unaudited)          | (Unaudited)           | (Unaudited)  | (Unaudited)   | (Unaudited)   | (Audited)   |
| <b>1 Income from operations</b>  |                      |                       |  |   |   |   |
| (a) Net Sales/Income from operations<br>(Net of excise duty)   | 2,655.57             | 3,278.77              | 2,018.12   | 8947.04   | 13438.49  | 16185.21  |
| (b) Other Operating Income   | 208.02               | 129.32                | 70.80  | 500.48  | 572.33  | 808.21  |
| <b>Total income from operations (net)</b>  | <b>2,863.59</b>      | <b>3,408.09</b>       | <b>2,088.92</b>  | <b>9,447.52</b>   | <b>14010.82</b>   | <b>16,993.42</b>  |
| <b>2 Expenses</b>  |                      |                       |  |   |   |   |
| (a) Cost of Materials Consumed   | 1,221.66             | 1,115.66              | 881.20   | 3265.20   | 5445.95   | 6744.15   |
| (b) Purchase of traded goods   | 335.94               | 696.49                | 244.01   | 1691.69   | 3188.29   | 3670.50   |
| (c) Change in inventories of finished goods,<br>work-in-progress and stock-in-trade,                       | -94.20               | 82.71                 | 119.45   | 17.57   | -40.83  | -194.96   |
| (d) Employee benefits expense  | 327.72               | 298.94                | 284.37   | 925.49  | 1583.63   | 1967.02   |
| (e) Depreciation and amortisation expense  | 126.59               | 127.64                | 143.21   | 377.77  | 715.31  | 864.90  |
| (f) Other expenses   | 587.88               | 571.13                | 500.66   | 1738.57   | 2757.52   | 3301.88   |
| <b>Total expenses</b>  | <b>2,505.59</b>      | <b>2,892.57</b>       | <b>2,172.90</b>  | <b>8016.29</b>  | <b>13649.87</b>   | <b>16353.49</b>   |
| <b>3 Profit/(Loss) from Operations before Other<br/>Income, Finance cost and Exceptional items (1-2)</b>   | <b>358.00</b>        | <b>515.52</b>         | <b>-83.98</b>  | <b>1431.23</b>  | <b>360.95</b>   | <b>639.93</b>   |
| 4 Other Income   | 14.09                | 119.29                | 81.64  | 196.11  | 289.31  | 409.05  |
| <b>5 Profit/(Loss) from ordinary activities before<br/>finance cost and exceptional items (3+4)</b>        | <b>372.09</b>        | <b>634.81</b>         | <b>-2.34</b>   | <b>1627.34</b>  | <b>650.26</b>   | <b>1048.98</b>  |
| 6 Finance costs  | 465.96               | 481.45                | 576.85   | 1434.50   | 2475.57   | 3035.87   |
| <b>7 Profit/(Loss) from ordinary activities after finance<br/>costs but before exceptional items (5+6)</b> | <b>-93.87</b>        | <b>153.36</b>         | <b>-579.19</b>   | <b>192.84</b>   | <b>-1825.29</b>   | <b>-1986.89</b>   |
| <b>8 (i) Exceptional Items (Net)</b>   |                      |                       |  |   |   |   |
| a Profit On Sale Of Fixed Assets   | 1033.69              | -                     | 272.58   | 1033.69   | 134.33  | -   |
| b Foreign Currency Monetary Item Translation   | -                    | -                     | -  | -   | -20.39  | -   |
| c Amortization of Expenses for restructuring   | -12.48               | -12.48                | -  | -37.46  | -   | -12.49  |
| d Excess provision written back  | -                    | -                     | -  | 62.21   | -   | 1246.71   |
| <b>8 Total Exceptional items(Net)</b>  | <b>1021.21</b>       | <b>-12.48</b>         | <b>272.58</b>  | <b>1058.44</b>  | <b>113.94</b>   | <b>1234.22</b>  |
| (ii) Provision for Taxation of earlier years   | -                    | -0.39                 | -  | -0.39   | -   | -   |
| <b>9 Profit/(Loss) from Ordinary Activities<br/>before tax (7+8)</b>                                       | <b>927.34</b>        | <b>140.49</b>         | <b>-306.61</b>   | <b>1250.89</b>  | <b>-1711.37</b>   | <b>-752.67</b>  |
| 10 Tax Expenses  | -25.00               | -                     | -  | -25.00  | -   | -   |
| <b>11 Net Profit/(Loss) from Ordinary activities<br/>after tax (9+10)</b>                                  | <b>902.34</b>        | <b>140.49</b>         | <b>-306.61</b>   | <b>1225.89</b>  | <b>-1711.37</b>   | <b>-752.67</b>  |
| 12 Extraordinary Item (net of tax expenses)  | -                    | -                     | -  | -   | -   | -   |
| <b>13 Net Profit/(Loss) for the period (11+12)</b>   | <b>902.34</b>        | <b>140.49</b>         | <b>-306.61</b>   | <b>1225.89</b>  | <b>-1711.37</b>   | <b>-752.67</b>  |
| 14 Share of Profit/(Loss) of associates  | -                    | -                     | -  | -   | -   | -   |
| 15 Minority interest   | 365.39               | 99.04                 | -76.70   | 552.43  | -191.86   | -63.01  |



# Lyka Labs Limited



## MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,  
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry @ lykalabs.com

### STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2012

| Particulars  | 3 Months Ended | 3 Months Ended | Corresponding                                   | Year To Date  | Year To Date   | (Rs.in Lacs)   |
|--|----------------|----------------|---|---|--|--|
|  | 31-Dec-2012    | 30-Sept-2012   | 3 Months Ended in the previous year 31-Dec-2011 | Figures For Current period ended 31-Dec-2012 (9 months) | Figures For the period ended 31-Dec-2011 (15 months) | Previous Accounting year ended 31-March-2012 (18 months) |
|  | (Unaudited)    | (Unaudited)    | (Unaudited)                                     | (Unaudited)   | (Unaudited)  | (Audited)  |
| 16 Net Profit/ (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15) | 536.95         | 41.45          | -229.91   | 673.46  | -1903.24   | -689.66  |
| 17 Paid up equity share capital ( face value Rs.10/- per share)  | 2158.00        | 2158.00        | 2158.00   | 2158.00   | 2158.00  | 2158.00  |
| 18 Reserve excluding Revaluation Reserve as per Balance Sheet of previous accounting year                  | -              | -              | -   | -   | -  | 3,525.69   |
| 19 i. Earnings Per Share (before extraordinary items) (of Rs 10/-each (not annualised)                     |                |                |   |   |  |  |
| (a) Basic  | 2.49           | 0.19           | -1.42   | 3.12  | -7.93  | 3.25   |
| (b) Diluted  | 2.49           | 0.19           | -1.42   | 3.12  | -7.93  | 3.25   |
| 19 ii. Earnings Per Share (After extraordinary items) (of Rs 10/-each (not annualised)                     |                |                |   |   |  |  |
| (a) Basic  | 2.49           | 0.19           | -1.42   | 3.12  | -7.93  | 3.25   |
| (b) Diluted  | 2.49           | 0.19           | -1.42   | 3.12  | -7.93  | 3.25   |
| <b>A PARTICULARS OF SHAREHOLDING</b>   |                |                |   |   |  |  |
| 1 Public Shareholding  |                |                |   |   |  |  |
| - Number of shares   | 16552735       | 16552735       | 16552735  | 16552735  | 16552735   | 16552735   |
| - Percentage of shareholding   | 76.70          | 76.70          | 76.70   | 76.70   | 76.70  | 76.70  |
| 2 Promoters and promoter group - Shareholding  |                |                |   |   |  |  |
| a. Pledged / Encumbered  |                |                |   |   |  |  |
| - Numbers of Shares  | 4665615        | 4965615        | 4981515   | 4665615   | 4981515  | 4965615  |
| - Percentage of shares (as a % of the total shareholding of promoter and promoter group                    | 92.81          | 98.77          | 99.09   | 92.81   | 99.09  | 98.77  |
| - Percentage of shares (as a % of the total share capital of the company)                                  | 21.62          | 23.01          | 23.08   | 21.62   | 23.08  | 23.01  |
| b. Non - encumbered  |                |                |   |   |  |  |
| - Number of shares   | 361650         | 61650          | 45750   | 361650  | 45750  | 61650  |
| - Percentage of shares (as a % of the total shareholding of promoter and promoter group                    | 7.19           | 1.23           | 0.91  | 7.19  | 0.91   | 1.23   |
| - Percentage of shares (as a % of the total share capital of the company)                                  | 1.68           | 0.29           | 0.22  | 1.68  | 0.22   | 0.29   |

| PARTICULARS                                    | 3 Month ended |
|--|---------------|
| <b>B INVESTOR COMPLAINTS</b>                   |               |
| Pending at the beginning of the quarter        | -             |
| Received during the quarter                    | 2             |
| Disposed of during the quarter                 | 2             |
| Remaining unresolved at the end of the quarter | -             |




## Notes:


1. The above results were duly considered by the Audit Committee on 14<sup>th</sup> February, 2013, and taken on record by the Board of Directors of the Company along with Limited Review Report carried out by the Auditors at its meeting held on 14<sup>th</sup> February, 2013.
2. Limited Review financial results for the quarter ended 31/12/2012 have been consolidated with that of Lyka BDR International Ltd., as approved by their Board.
3. During the quarter Company has charged Rs.19.04 lacs being depreciation on revalued assets.
4. During the Quarter, the Company has capitalised interest of Rs.19.95 lacs towards the Term Loan for Tarapur Upgradation, Ankleshwar Expansion and R & D unit and Rs.28.39 lacs towards pending allocation to Intangible Assets.
5. The Company's factory at Tarapur is under upgradation. In view of this, the production has been suspended.
6. The Company has one Single Segment "Pharmaceuticals".
7. Previous periods figures have been regrouped/rearranged wherever necessary.
8. Audit qualifications in respect of Audited Accounts for 2010-2012 and management comments thereon are detailed below :

Regarding the Revaluation of its Fixed Assets in the earlier year and writing off/adjustment of stocks, overdue debtors, loans & advances and deferred revenue expenditure, the management is of the view that such extra-ordinary items relating to the past years could legitimately be written off against the 'net present replacement value' and during the year, profit on sale of revalued assets is the "actual profit" realised and the remaining assets belonging to the Company have significantly higher "present replacement values" the management is of the view that such extra-ordinary items is legitimately credited as the Profit on Sale of Assets.

9. In the case of subsidiary company Lyka BDR International Ltd.,
  - 1) Note No. 2: mentions of the Contingent Liability which in the opinion of the management do not warrant any provisions because of the nature stated therein.
  - 2) Note No. 13: deal with Loans & Advances, Sundry Debtors & Sundry Creditors which are pending as on the date of the Balance sheet and are being addressed subsequently thereof.

For L YKA LABS LIMITED

  
(N. I. GANDHI)  
Chairman & Managing Director

  
Mumbai  
14-Feb-13.